Akute myeloische Leukämie
AML: Medigene CD-TCR-001
A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR modified T cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms.Read More
AML: UC02-123-01
Multicenter, open-label, adaptive design phase I trial with genetically modified T-cells carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of patients with hematologic and lymphatic malignancies ...Read More
AML: Army 1
First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid LeukemiaRead More
AML: AMG 427 20170528
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia.Read More
AML: GEM333-01
A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM333, a CD33 Targeted Bispecific Anti- body Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia.Read More